These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 14982156)

  • 1. Strategies for dealing with reactive intermediates in drug discovery and development.
    Nassar AE; Lopez-Anaya A
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):126-36. PubMed ID: 14982156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for dealing with metabolite elucidation in drug discovery and development.
    Nassar AE; Talaat RE
    Drug Discov Today; 2004 Apr; 9(7):317-27. PubMed ID: 15037231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for reactive intermediates and toxicity assessment in drug discovery.
    Caldwell GW; Yan Z
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):47-60. PubMed ID: 16445117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural alerts, reactive metabolites, and protein covalent binding: how reliable are these attributes as predictors of drug toxicity?
    Kalgutkar AS; Didiuk MT
    Chem Biodivers; 2009 Nov; 6(11):2115-37. PubMed ID: 19937848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of a new drug's potential to cause idiosyncratic reactions.
    Uetrecht J
    Curr Opin Drug Discov Devel; 2001 Jan; 4(1):55-9. PubMed ID: 11727323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idiosyncratic drug reactions: past, present, and future.
    Uetrecht J
    Chem Res Toxicol; 2008 Jan; 21(1):84-92. PubMed ID: 18052104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
    Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans.
    Masubuchi N; Makino C; Murayama N
    Chem Res Toxicol; 2007 Mar; 20(3):455-64. PubMed ID: 17309281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving the decision-making process in structural modification of drug candidates: reducing toxicity.
    Nassar AE; Kamel AM; Clarimont C
    Drug Discov Today; 2004 Dec; 9(24):1055-64. PubMed ID: 15582794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations.
    Srinivas NR
    Biomed Chromatogr; 2006 May; 20(5):383-414. PubMed ID: 16307470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions.
    Uetrecht JP
    Drug Metab Rev; 1992; 24(3):299-366. PubMed ID: 1628536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting drug-drug interactions in drug discovery: where are we now and where are we going?
    Hutzler M; Messing DM; Wienkers LC
    Curr Opin Drug Discov Devel; 2005 Jan; 8(1):51-8. PubMed ID: 15679172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applications of high-throughput ADME in drug discovery.
    Kassel DB
    Curr Opin Chem Biol; 2004 Jun; 8(3):339-45. PubMed ID: 15183334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: are we all the way there yet?
    Nassar AE; Talaat RE; Kamel AM
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):61-74. PubMed ID: 16445118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idiosyncratic toxicity: mechanistic insights gained from analysis of prior compounds.
    Waring JF; Anderson MG
    Curr Opin Drug Discov Devel; 2005 Jan; 8(1):59-65. PubMed ID: 15679173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development.
    Whitebread S; Hamon J; Bojanic D; Urban L
    Drug Discov Today; 2005 Nov; 10(21):1421-33. PubMed ID: 16243262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug bioactivation and protein adduct formation in the pathogenesis of drug-induced toxicity.
    Park BK; Laverty H; Srivastava A; Antoine DJ; Naisbitt D; Williams DP
    Chem Biol Interact; 2011 Jun; 192(1-2):30-6. PubMed ID: 20846520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idiosyncratic reactions and metabolism of sulfur-containing drugs.
    Zuniga FI; Loi D; Ling KH; Tang-Liu DD
    Expert Opin Drug Metab Toxicol; 2012 Apr; 8(4):467-85. PubMed ID: 22394356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxidases: a role in the metabolism and side effects of drugs.
    Tafazoli S; O'Brien PJ
    Drug Discov Today; 2005 May; 10(9):617-25. PubMed ID: 15894226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.